Court upholds Endo patent ruling

The U.S. District Court for the Southern District of New York has issued an order upholding its August 2015 ruling in Endo’s favor and confirming the court’s prior injunction against the manufacture or sale of the generic version of non-crush-resistant Opana. Opana ER is an extended-release narcotic pain reliever used to treat moderate to severe pain. Actavis, the U.S. generics business of Allergan (NYSE: AGN), is marketing a non-crush-resistant generic version of Opana ER. Roxane Laboratories…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news